Compare TKO Group Holdings Inc (TKO) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TKO Group Holdings Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? TKO Group Holdings Inc trades at $181.73 (market cap $13.06B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 9.8× TKO Group Holdings Inc's market cap, and TKO Group Holdings Inc pays a 1.77% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold TKO Group Holdings Inc for 30 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| TKO | VRTX | |
|---|---|---|
Market Cap | $13.06B | $128.16B |
Volume | 999,906 | 806,603 |
Sector | Media | Health |
52-Week High | $224.96 | $557.96 |
52-Week Low | $175.58 | $407.37 |
Typical Hold Time | 30 Days | 120 Days |
Enterprise Value | $17.42B | $122.29B |
Dividend Yield | 1.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TKO trades at $178.64, down 1.24% on the day and near a 52-week low of $174.58 (Defense World, 2026-10-02). The stock is technically bearish with mixed earnings, missing Q2 2026 EPS estimates but beating Q1. Revenue growth is solid, with 2026 guidance raised to $5.3B, though high P/E of 62.68 signals premium valuation. A quarterly dividend of $0.79 was declared for September 2026.
Outlook is supported by strong analyst consensus (89% buy ratings) and a $227 price target, but risks include recent technical weakness, margin pressure, and competitive threats. The stock offers upside if media rights and live event execution drive earnings growth, yet volatility near lows warrants caution.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
